Key clinical point: A novel anti-CD45 targeted conditioning regimen appears safe and feasible in older patients with relapsed or refractory acute myeloid leukemia undergoing transplant.
Major finding: Treatment with iodine-131 apamistamab has so for resulted in successful engraftment for all patients who have received it and gone on to transplant.
Study details: Early results from SIERRA, a randomized, phase 3 trial, including data on 38 patients enrolled to date.
Disclosures: The study is supported by Actinium Pharmaceuticals. Dr. Giralt reported disclosures related to Actinium and several other companies.
Giralt SA et al. TCT 2019, Abstract LBA3.